Therapeutic strategy for patients with pN0 gastric carcinoma
β Scribed by Chikara Kunisaki; Hiroshi Shimada; Masato Nomura; Goro Matsuda; Yuichi Otsuka; Hidetaka Ono; Hirotoshi Akiyama
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 102 KB
- Volume
- 94
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
β¦ Synopsis
Background and Objectives: The prognosis for patients with pN0 gastric cancer is moderately hopeful (expected 5-year survival: 80%). However, the relevant prognostic factors and most appropriate surveillance protocol have not been identified. Methods: We investigated 733 gastric cancer patients without lymph node metastasis for prognostic factors by uni-and multi-variate analysis and by documenting causes of death and recurrence patterns. Results: Univariate analysis revealed that age, tumor location, macroscopic appearance, tumor diameter, invasion depth, lymphatic invasion, and venous invasion affected prognosis. Multivariate analysis showed that age (!60 years), ill-defined macroscopic appearance, and undifferentiated histological type independently reduced survival rates. Age (!60 years) and undifferentiated histological type adversely influenced prognosis in 507 early gastric cancer patients whereas ill-defined macroscopic appearance adversely affected prognosis in 226 advanced cancer patients. Recurrence patterns in these patients were similar to those produced by lymph node metastasis. The predominant recurrence pattern was peritoneal dissemination, observed 2-3 years post-resection. Conclusions: This study identified adverse prognostic factors in pN0 gastric cancer patients. Randomized controlled studies of adjuvant chemotherapy are necessary to assess whether such therapy is beneficial for patients with adverse prognostic factors.
π SIMILAR VOLUMES
transducer) in the pouch during the first 10min of defaecation suggests that the catheter has either fallen out or is not recording accurately. Could the anal canal microtransducers be recording atmospheric pressure at this point? The clinical results in this series are encouraging to those conside
Living donor liver transplantation (LDLT) has evolved to represent an important surgical strategy for patients with hepatocellular carcinoma (HCC). However, due to disadvantages, including donor risks and higher rates of perioperative complications, LDLT has been considered as a second-line treatmen
## BACKGROUND. Breast carcinoma in the setting of liver metastases and jaundice raises a complex therapeutic dilemma. Not only is the prognosis poor but toxicity related to treatment can be unpredictable due to altered drug clearance. Guidelines built around dose reduction have been suggested but